• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study: Pharma should invest in public health campaigns

Study: Pharma should invest in public health campaigns

April 19, 2011
CenterWatch Staff

Pharmaceutical companies should consider investing in public health campaigns as a way to help with the challenges facing healthcare systems, according to a report discussed in Pharma Times.

The study was conducted by the Economist Intelligence Unit and commissioned by Digitas Health Europe.  It questioned 450 healthcare professionals in Europe, Latin America, China and India and discovered that 32.4% believed investing in public health campaigns was an important factor for pharmaceutical companies.

Nearly 100% of the respondents stated that awareness campaigns that focus on preventative medicine and encourage people to take control of their own health were a valuable part of the industry.

About 70% of healthcare professionals felt chronic metabolic diseases, such as diabetes, as their country’s primary challenge; ageing populations was next at 34.4%; infectious diseases can in at 25.8% and drug and alcohol abuse at 23%.

Overall, the biggest challenge to the countries’ healthcare systems was lack of funding, health care providers reported.

Iain Scott, managing editor at the Economist Intelligence Unit, said the research revealed what the industry was facing: “There’s also a clear indication of where pharma companies ought to place themselves. Doctors value the information they receive from drug firms and they see a big role for pharma in helping take some pressure off healthcare systems by supporting public health campaigns.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing